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INTRODUCTION: A high proportion of patients with metastatic prostate cancer
(mPC) have bone metastases (BM) which are associated with a high level of mor-
bidity, including bone pain and skeletal related events. Although the epidemiology
of prostate cancer is well documented in the United Kingdom, data on the stage at
diagnosis, survival of metastatic cancer and data on incidence / prevalence of BM
subsequent to prostate cancer are surprisingly scarce for such a common disease.
OBJECTIVES: To develop a disease model to estimate the number of men with BM
due to PC in the UK from 2010 to 2020. METHODS: A four-stage disease model
(non-mPC,mPC, death from PC, death-other causes), simulating the progression of
PC was developed to estimate the incidence and prevalence of mPC and BM in the
United Kingdom. The incidence-based model was run over 50 years to obtain inci-
dence and prevalence data. A 1-year cycle length was used. Inputs were obtained
from published official sources. Validation used UK national statistics on number
of cases / deaths with PC. After validation, a BM-component was fitted within the
PC model to ensure consistency with the UK national statistics and obtain esti-
mates of the future incidence and prevalence of BM in the United Kingdom.
RESULTS: The model estimated an increase in new patients with PC from 2006 to
2020 from 35,510 to 47,417.mPC patientswill increase from20,000 (1990) to 66,100
(2020). Assuming a 30% prevalence of BM and a RR of 1.35 for survival with BM
compared to visceral metastases, the number of PC diagnosed men living with BM
ranges from 6,000 (1995) to 16,200 (2020). CONCLUSIONS: This disease model
shows that the prevalence of PC is expected to increase in the UK. A substantial
number of patients with mPC will develop BM though this is expected to be stable.
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INTRODUCTION: Approximately 65-75% of patients with metastatic breast cancer
(mBC) suffer from bone metastases (BM). Complications include pain, impaired
mobility, hypercalcemia and pathologic fractures, affecting quality of life and prog-
nosis. The epidemiology of breast cancer is well documented. Data on the inci-
dence and prevalence of BM subsequent to breast cancer are scarce. OBJECTIVES:
To develop a diseasemodel to estimate the number of womenwith BC and BM due
to BC in the United Kingdom from 2010 to 2020.METHODS:A four-stage incidence-
based disease model (non-mBC, mBC, death from BC, death-other causes), simu-
lating the progression of BC was developed to estimate the incidence and preva-
lence ofmBC and BM in the UK. It was run over 50 years using a 1-year cycle length.
Inputs were obtained from published sources. Validation used UK national statis-
tics on number of cases / deaths with BC. After validation, a BM-component was
fitted within the BCmodel to ensure consistency with UK national statistics and to
obtain estimates of the future incidence and prevalence of BM from BC in the
UnitedKingdom.RESULTS:Newcases of BC in theUnitedKingdomare predicted to
reach 53,500 in 2020. Deaths due to BC are expected to decrease from 15,750 to
11,300 deaths in 2020. Cases of mBC will likely remain stable at 25,500 cases.
Assuming a 54% prevalence of BM in mBC, a RR of 1.42 for survival with-BM versus
other-BM, the number of women with BM is assumed to remain stable at 14,000.
CONCLUSIONS: Thismodel provides new data for BMs in BC. Predictions are in line
with expectations from official sources. The model shows that a substantial num-
ber of women with BC will develop BM. Because of the large female population
living with mBC, a significant opportunity remains to improve outcomes in pa-
tients with BM.
PCN20
EXERCISE LOWERS ESTROGEN AND PROGESTERONE LEVELS IN
PREMENOPAUSAL WOMEN AT HIGH RISK OF BREAST CANCER
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OBJECTIVES: Experimental and clinical data support a role for estrogens in the
development and growth of breast cancer, and lowered estrogen exposure reduces
breast cancer recurrence and new diagnoses in high-risk women. There is varied
evidence that increased physical activity is associated with breast cancer risk re-
duction in both pre- and postmenopausal women, perhaps via lowered estrogen
levels. The purpose of this study was to assess whether exercise intervention in
premenopausal women at increased breast cancer risk reduces estrogen or proges-
terone levels. METHODS: Seven healthy premenopausal women at high risk for
breast cancer completed a seven-menstrual-cycle study. The study beganwith two
pre-intervention cycles of baseline measurement of hormone levels via daily first-
morning urine collection, allowing calculation of average area-under-the-curve
(AUC) hormone exposure across the menstrual cycle. Participants then began 5
cycles of exercise training to maintenance of 300 minutes per week at 80-85% of
maximal aerobic capacity. During the last two exercise cycles, urinary estradiol
and progesterone levels were again measured daily. RESULTS: Total estrogen ex-
posure declined by 18.9% and total progesterone exposure by 23.7%. Declines were
mostly due to decreased luteal phase levels, though menstrual cycle and luteal
phase lengths were unchanged. CONCLUSIONS: The study demonstrated the fea-
sibility of daily urine samples and AUCmeasurement to assess hormone exposure
in experimental studies of the impact of interventions on ovarian hormones. The
results suggest value in exercise interventions to reduce hormone levels in high-
risk women with few side effects and potential for incremental benefits to surgical
or pharmacologic interventions.
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OBJECTIVES: This study evaluated rates of treatment modifications and reasons
for these changes among patients treated with angiogenesis inhibitors in Irish
clinical practice. METHODS: Data from medical records were retrospectively re-
viewed at 3 large oncology centers in Ireland for mRCC patients who were 18
years and received sunitinib (N54), sorafenib (N9), bevacizumab (N6), or tem-
sirolimus (N7) as first-line treatment from January 1, 2005 to August 31, 2010.
Proportions of patients with treatment discontinuation, interruption, or dose
change, and reasons formodifications and time tomodifications were determined.
RESULTS: Due to small sample sizes in other groups, only results for sunitinib are
summarized. Patients totaling 1.9% had prior cytokine therapy. Median first-line
angiogenesis inhibitor treatment duration for sunitinib was 8.7 months. A total of
87% of patients treated with first-line sunitinib experienced1 adverse event (AE);
18.5% experienced 1 grade 3/4 AE. 70.4% of patients discontinued first-line
sunitinib mainly due to progressive disease (38.9%). AEs were the main reason for
treatment interruption among 20 (37%) patients that had an interruption. A total of
94.4% of patients started treatment on 50 mg QD 4/2 dosing; 33.3% of them were
dose reduced to 37.5mg QD 4/2 withmedian time to reduction 2.7months. Overall,
77.8% of the patients had 1 treatment modification. Adverse events led to treat-
ment modifications in 42.6% of patients. Among patients who discontinued treat-
ment, 31.6% discontinued within 18 weeks (15.8% within 0-6 weeks, 7.9% in 7-12
weeks, and 7.9% in 13-18 weeks). Among patients who discontinued treatment
within 18 weeks, 66.7% discontinued due to AEs. CONCLUSIONS: Over three-quar-
ters of sunitinib patients experienced treatmentmodifications, more than half due
to AEs. About 24% of treatment discontinuations occurred within the first 2 cycles.
This real-world practice study suggests that treatment tolerability is a challenge for
physicians in the clinical care of mRCC patients.
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ASSESSMENT OF SAFETY PROFILE OF TRASTUZUMAB IN METASTATIC BREAST
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OBJECTIVES: Trastuzumab is a recently approved monoclonal antibody for the
treatment of HER2 positive women with metastatic breast cancer (MBC). It shows
less toxicity than cytotoxic chemotherapy. The objective of this review was to
assess the safety profile of trastuzumab monotherapy in the treatment of HER2
positive women with MBC.METHODS: A comprehensive search was conducted in
the Cochrane Library, EMBASE and PUBMED to identify randomised controlled
trials (RCTs) and single-arm studies assessing the safety of trastuzumab, as mono-
therapy, in adult HER2 positive women with MBC. The searches were conducted
from the database start to January 2011. Only English language studies were in-
cluded. Eligibility of trials was assessed by two blinded reviewers with any discrep-
ancy resolved by a third independent reviewer. Adverse events were the outcome
of interest. RESULTS: A total of 518 citations were retrieved of which five studies
met the inclusion criteria. This constituted a total of 2229 patients. Safety data
showed that gastrointestinal adverse effects (6.68%) were most frequent fol-
lowed by decrease in left ventricular ejection fraction (LVEF) (6.59%), infection
(3.86%), pain (3.14%), headache (2.87%), chills (2.33%), congestive heart failure
(1.93%), cough (1.84%), fatigue (1.44%), dyspnoea (1.21%) and pyrexia (0.76%).
CONCLUSIONS: Results show a higher incidence of gastric and cardiac adverse
events compared to other adverse events. Long term studies are required to eval-
uate risks that may be associated with trastuzumab.
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OBJECTIVES: To determine whether the issuance of a new or revised Black Box
Warning (BBW) for an Adverse Drug Reaction (ADR) by US Food and Drug Admin-
istration (FDA) increases the proportional reporting of the ADR to the FDA’s Ad-
verse Event Reporting System (AERS). METHODS: We compiled a list of Multiple
Myeloma (MM) drugs with BBWs issued after the drug approval: melphalan, tha-
lidomide, vincristine, carmustine, and doxorubicin. We searched the AERS data-
base for MM drugs and ADRs listed in BBWs and retrieved all cases. We calculated
the empiric bayes geometric mean (EBGM) values and clinical outcomes (chi-
square analyses) for each drug and ADR combination and compared them before
and after the issuance of the BBW. RESULTS: EBGM signals increased for 8 of 10
BBW drug/events: melphalan/leukemia (12.83 to 15.97); melphalan/chromosomal
aberrations (0 to 18.677); melaphalan/bone marrow suppression (5.926 to 7.629);
thalidomide/venous thrombosis (1.201 to 2.464); intrathecal vincristine/death
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(1.690 to 6.852); doxorubicin/congestive heart failure (1.154 to 5.004); and carmus-
tine/leukopenia (3.796 to 5.650) and thrombocytopenia (3.796 to 5.644). Further-
more, the percentage of AERS reports associated with outcomes of hospitalization
increased as follows: melphalan causing leukemia (0% to 37%, p0.001), chromo-
somal aberrations (0% to 15.55%, p0.001), bone marrow suppression (4.0% to
40.9%, p0.001), or hypersensitivity (30.77% to 50.0%, p0.01). The mortality out-
come increased only formelphalan/leukemia (8.9% to 54.8%, p0.001). Life-threat-
ening outcomes increased for melphalan/leukemia (0% to 17.7%, p0.016), mel-
phalan/chromosomal aberrations (0 to 8.7%, p0.001), carmustine leukopenia (0
to 17.7%, p0.016), and carmustine/thrombocytopenia (0-20.3%, P0.045).
CONCLUSIONS: Prior to the BBWs, health professionals do not appear to associate
the ADRs with the drug and/or do not report the events to the FDA. Issuance of
BBWs appears to result in increased awareness and reporting. Since pre-marketing
research may not identify rare ADRs and voluntary post-marketing reporting may
be inadequate, proactive pharmacovigilance programs should be implemented.
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FACTORS ASSOCIATED WITH LATE-STAGE PROSTATE CANCER SURVIVAL IN
FLORIDA
Adunlin GB, Xiao H
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OBJECTIVES: 1) Examine survival of late stage prostate cancer patients; and 2)
Determine factors associated with survival at both the patient and neighborhood
levels. METHODS: Prostate cancer cases were obtained from the Florida Cancer
Data System. Men aged 40 years and above diagnosed with late prostate cancer in
1995 were followed through 2000. Demographics, health insurance and vital sta-
tistics were extracted for individual patients and linked with Florida Census 2000
data with education and poverty level information. Data was analyzed using a
multilevel logistic regression to examine the relationship of prostate cancer sur-
vival with both patient-level characteristics and area-based measures of socioeco-
nomic status.RESULTS:Atotal of 1,101menwerediagnosed in Floridawith late stage
prostate cancer in 1995 with an average age of 69 years. Patients with the following
characteristics were more likely to die from prostate cancer than their counterparts:
unmarried, Medicaid recipient, and older. Men residing in neighborhood with higher
percentage of high school education and surprisingly men without health insurance
weremore likely to live longer than five years.CONCLUSIONS: Although survival has
improvedover timedue to early detectionof prostate cancer, there are still differences
in survival among men diagnosed with late stage based on different marital status,
health insurance and neighborhood characteristics.
Cancer – Cost Studies
PCN25
BUDGET-IMPACT OF ERIBULIN FOR THIRD-LINE TREATMENT OF METASTATIC
BREAST CANCER IN A UNITED STATES MANAGED CARE SETTING
Tao C1, Taylor D1, Parthan A2, Faria C3, Choe Y3
1i3 Innovus, Medford, MA, USA, 2i3 Innovus, San Francisco, CA, USA, 3Eisai, Inc., Woodcliff
Lake, NJ, USA
OBJECTIVES: Eribulin is a non-taxane microtubule dynamics inhibitor that has
demonstrated improved overall survival in a phase III study relative to commonly
used therapies in late-line metastatic breast cancer (MBC). This budget impact
model (BIM) was developed to help US payers make informed decisions regarding
addition of eribulin for the management of MBC.METHODS: From the perspective
of US commercial payers, an Excel-based BIMwas constructed upon a hypothetical
plan of 1 million members. 600 women are estimated to be newly diagnosed with
breast cancer; of these 5% with MBC and 24% are initiated on 3rd-line chemother-
apy, 47% of these on monotherapy. A Markov decision-analytic model was used to
tracemovement of patients receiving eribulin or another 3rd-line single-agent che-
motherapies through different MBC states (treatment initialization, stable, re-
sponse, progression, death). The model used a two-year time horizon with one-
week Markov cycle lengths. The efficacy, market shares, and medical and drug
costs were derived using published and internally available data sources. Model
probabilities were based on discontinuation, progression free survival, and overall
survival rates from the EMBRACE trial. Market share of eribulin was assumed to be
5% in year-one and 10% in year-two of the model. Model outcomes included: total
costs over 2 years pre- and post-inclusion of eribulin, net costs, cost per member
permonth (PMPM), cost per patient permonth (PPPM) andmedian overall survival.
RESULTS: Of the 1 million plan members, approximately 3 incident cases of MBC
requiring 3rd line treatment were identified each year. Budgetary impact PMPM
was estimated to be $0.01 in year-one and year-two, and PPPM $118 and $252,
respectively. Overall net budgetary impact for year-one and year-two was $4,880
and $10,450, respectively. CONCLUSIONS: Based on this analysis adding eribulin
does not exhibit a significant overall cost increase when taking into account med-
ical and drug expenditures.
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OBJECTIVES: Skeletal complications from bonemetastases can be debilitating and
costly. Denosumab was recently approved in the US for SRE prevention in patients
with bonemetastases from solid tumors. This study evaluated the three-year bud-
get impact of denosumab compared to zoledronic acid (ZA) for breast and prostate
cancer using the US managed care perspective. METHODS: Excel-based models
compared denosumab (120mg) to ZA (4 mg) administered every four weeks for the
patient lifetime. Inputs included the US population age and gender distribution,
Medicare managed care enrollment rates, the prevalence of bone metastases (es-
timated from literature-based epidemiological simulations), and 2010 costs for
therapy and SREs. Utilization estimates assumed that 66% of breast and 48% of
prostate cancer patients with bone metastases would receive anti-resorptive ther-
apy and that for years one to three 20%, 35% and 45% of these patients would use
denosumab. Trial-based SRE rates per patient-year were 0.488 and 0.631 (deno-
sumab and ZA) for breast cancer and 0.746 and 0.947 for prostate cancer. The
expected incremental adverse event cost was nominal and therefore excluded.
Sensitivity analyses were conducted to identify influential variables on the incre-
mental costs per member per month (PMPM). RESULTS: The incremental PMPM
costs for years one to three were $0.02, $0.04, and $0.05 ($0.11 total) for breast
cancer and $0.01, $0.02, and $0.03 ($0.06 total) for prostate cancer. For both tumor
types, influential variables included costs for denosumab and ZA, prevalence rates
of each cancer and of bonemetastases, utilization rates of denosumab and ZA, and
underlying SRE rates. The younger breast cancer age distribution results in a larger
incremental cost burden for managed care organizations when compared to pros-
tate cancer. CONCLUSIONS: The real-world financial impact to US health plans
from using denosumab should be relatively modest and will vary depending on
prevalence and utilization patterns.
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OBJECTIVES: Skeletal complications from bone metastases impose a significant
clinical and economic burden on patients and health systems. Zoledronic acid (ZA)
has been the mainstay for prevention of skeletal related events (SREs) in patients
with bonemetastases. In 2010, FDA approved denosumab for prevention of SREs in
patients with solid-tumor bone metastases. We assessed the financial impact to a
managed-care plan of adding denosumab to a ZA-only formulary for this
indication.METHODS:We developed an Excel-based model to evaluate the trajec-
tory of spending over 1-3 year time horizons in a hypothetical managed care plan
with 1 million members and 688 patients with solid-tumor bone metastases. The
model considered use and associated costs of drug acquisition and administration,
SRE management, and adverse event (AE) treatment under two scenarios: (1) Base
Case—ZA-only formulary; and (2) Restricted Formulary—denosumab limited to sec-
ond-line treatment in patients failing ZA. SREs included pathologic fracture, ther-
apeutic radiology, spinal cord compression, and orthopaedic surgery. AEs included
osteonecrosis of the jaw, renal problems, acute phase reactions, andhypocalcemia.
Model parameters were derived from published literature, product labels, clinical
trial data, and administrative cost databases. Drug costs were based on published
wholesale acquisition cost minus copayments. Costs were stated as 2010 US
dollars. RESULTS: In the Base Case scenario (ZA only), total costs were $10.8 million
per year. Allowing restricted access to denosumab was associated with total
costs of $11.4, $11.6, and $11.7 million over 1, 2, and 3 years ($0.05, $0.06, $0.08
incrementally per-member per-month). The corresponding incremental cost of
adding denosumab was $69, $94, and $115 per ZA-treated member per month.
CONCLUSIONS:With an acquisition cost nearly twice that of ZA, restricted use of
denosumab adds considerably to patient management costs. Incremental benefits
should be weighed carefully against these costs before considering coverage.
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OBJECTIVES: To evaluate the economic impact of intravenous iron (ferric carboxy-
maltose; Ferinject) in chemotherapy-induced ferriprive anemia in breast and gas-
trointestinal cancer.METHODS:We used an economicmodel which compared the
usual therapeutic strategies of anemia with or without intravenous iron. Costs
related to anemia treatment by ESA, blood transfusion and intravenous iron were
estimated and compared. Cost savingswere calculated from the French healthcare
payer perspective. Data included in the economic model were obtained from sci-
entific literature, public health agencies and medical experts. Impact of Ferinject
on the decrease of the number of blood transfusions at hospital and the decrease of
ESA dosing was evaluated. RESULTS: Patients treated with 2000 mg of Ferinject
during chemotherapy treatment and 1000 mg at home concomitantly with ESA
once every two month during 4 months. Based on the estimated decreased of the
25% ESA dosing when administered with Ferinject, and a decrease of 10% of pa-
tients receiving ESA after chemotherapy (expert opinion), the most prominent an-
nual cost savings were observed in chemotherapy-induced anemia in breast can-
cer (€881 and €319 by patient for metastatic and non-metastatic breast cancers,
respectively); global cost saving is estimated to €29millions. Regarding blood trans-
fusion the cost saving is estimated to €1.6 millions. Impact of Ferinject on the
decrease of ESA dosing in gastrointestinal cancer was evaluated on the same basis.
The annual cost saving is estimated to €6.6 millions. Analysis showed that strate-
gies including intravenous iron remained cost-effective even with wide variations
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